sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine

{
  "id": "MLC-T-ONC-016726",
  "term": "sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine",
  "field": "Oncology and biomedicine",
  "definition": "A vaccine consisting of the oligosaccharide antigen sialyl Lewisª (CA19-9) conjugated to the nonspecific immunomodulator keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Upon administration, sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine may induce production of IgG and IgM antibodies as well as trigger an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing the sialyl Lewisª antigen. Sialyl Lewisª is a blood group antigen and a tumor-associated antigen associated with epithelial cancers such as breast cancer and various digestive cancers. Sialyl Lewisª serves as a ligand for the cytokine-inducible cell adhesion molecule (CAM) E-selectin, an endothelial cell-specific type I transmembrane surface protein, thus facilitating hematogenous metastasis by mediating the adhesion of circulating cancer cells to vascular endothelium.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/sialyl-lewisa-keyhole-limpet-hemocyanin-conjugate-vaccine/"
}